Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Ligand Pharmaceuticals (LGNYZ) over the last 15 years, with Q3 2025 value amounting to $11.1 million.

  • Ligand Pharmaceuticals' Other Operating Expenses changed N/A to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.2 million, marking a year-over-year decrease of 2576.45%. This contributed to the annual value of $2.1 million for FY2023, which is N/A changed from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Other Operating Expenses stood at $11.1 million for Q3 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Other Operating Expenses registered a high of $37.7 million during Q2 2024, and its lowest value of $2.1 million during Q3 2023.
  • In the last 5 years, Ligand Pharmaceuticals' Other Operating Expenses had a median value of $12.3 million in 2023 and averaged $14.8 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Other Operating Expenses surged by 26886.76% in 2024, and later crashed by 6695.97% in 2025.
  • Ligand Pharmaceuticals' Other Operating Expenses (Quarter) stood at $3.8 million in 2021, then surged by 249.45% to $13.3 million in 2022, then tumbled by 84.03% to $2.1 million in 2023, then skyrocketed by 1675.29% to $37.7 million in 2024, then tumbled by 70.61% to $11.1 million in 2025.
  • Its last three reported values are $11.1 million in Q3 2025, $12.4 million for Q2 2025, and $12.7 million during Q1 2025.